MedTrace Logo

Omeza Products in Combination With Standard of Care for the Treatment of Diabetic Foot Ulcers

NCT05417425 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2024-06-21

No results posted yet for this study

Summary

This study is to evaluate the efficacy of OCM™ used in combination with off-loading devices for the treatment of diabetic foot ulcers.

Conditions

  • Diabetic Foot Ulcers

Interventions

COMBINATION_PRODUCT

Omeza collagen matrix, Omeza lidocaine lavage, Omeza skin protectant

The three omeza products were designed to be used in combination for the treatment of chronic wounds

Sponsors & Collaborators

  • Omeza, LLC

    lead INDUSTRY

Principal Investigators

  • Richard Simman, MD · ProMedica Physician Group

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2023-10-31
Completion
2023-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05417425 on ClinicalTrials.gov